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Introduction
The increasing use of tissue dosimetry estimated using pharmacokinetic models in chemical risk assessments in multiple countries across the globe is producing greater awareness of the need to develop internationally recognized good modelling practices.
These practices would facilitate sharing of models and model evaluations and consistent applications in risk assessments. Clear descriptions of good practices for, 1. model development (i.e., research and analysis activities), 2. model characterization (i.e., methods to describe how consistent the model is with biology and the strengths and limitations of available model and data, e.g., sensitivity analyses), 3. model documentation, and 4. model evaluation (i.e., independent review), would assist not only risk assessors who need to decide whether and how to use the models, but also model developers who need to know what is expected for various purposes (e.g., research versus application in risk assessment) (Cobelli, C. et al. 1984; Portier, C. J. and C. M. Lyles 1996; Rescigno, A. and J. S. Beck 1987) .
For risk assessors, good modelling practice would describe a path forward when seeking to evaluate the potential for a pharmacokinetic model, particularly a physiologically based pharmacokinetic (PBPK) model, to contribute to a risk assessment. Good modelling practices would only be one element, however, in a broader context that describes risk assessment practices ranging from limited information analyses (often referred to as default or screening analyses) to biological modelling of the toxicokinetics and toxicodynamic processes in animals and humans. The shift from 'default' through 'data-informed' approaches to risk assessment represents a 'continuum' of methods. The transition begins with default approaches which involve empirical observations made from broad databases of information that were not group, species or chemical specific and where pharmacokinetics and dynamics were not explicitly addressed. The next phase is 'categorical' and 'species-specific' approaches where substances and species are placed into categories based on their characteristics. The categorical approach is followed by the IPCS scheme which uses compound-related and/or chemical specific 4 adjustment factors (CSAF) (IPCS 2005) , that included chemical-specific pharmacokinetic or pharmacodynamic data. When appropriate, fully data-derived, chemical specific, biologically based dose response risk assessment methods can be employed for chemicals of high concern or with high economic impacts.
Descriptions of known or hypothesized modes of action (i.e., the toxicodynamic process) leading to the toxicity under consideration play key roles throughout much of the continuum of risk assessment methods. A framework for organizing and evaluating evidence supporting modes of action has been described, which is applicable to all toxicity endpoints (Seed, J. et al. 2005; Sonich-Mullin, C. et al. 2001; US EPA 2005) .
Additional steps to evaluate whether a mode of action would occur in humans based upon what was known from other animal species have also been presented (Boobis, A. R. et al. 2006; Boobis, A. R. et al. 2007; Seed, J. et al. 2005) . Application of toxicokinetic and toxicodynamic information in estimating values of factors accounting for interspecies extrapolation and human interindividual variability has been described (Gundert-Remy, U. and C. Sonich-Mullin 2002; IPCS 2005) . These factors may be addressed using appropriate data without a pharmacokinetic model or they may be replaced by application of PBPK models.
For modellers, GMPs are important because they describe the kinds of model characterization and documentation that will be considered in a model evaluation process when a model is considered for application in risk assessment. The initial creation of models, along with needed laboratory experimentation, can be a creative and unpredictable process that will be minimally altered by GMPs. However, even at this very early stage, awareness of GMPs can be valuable, including recommendations when publishing models in the peer reviewed literature (Andersen, M. E. et al. 1995) . For example, modellers often try several alternative structures as they attempt to reconcile the available data and the description of the biology in the model. These alternatives would not be documented to the same degree as a model proposed for use in risk assessment, but documenting these alternatives were considered important in supporting the model structure eventually selected ). Current Practice -Where do we stand?
To move forward effectively in developing GMPs, it is useful to understand current practices in PBPK modelling and its application in risk assessment. These applications are more widespread than has been commonly recognized. models applied in environmental regulation can also be informative in terms of their form, content, and processes.
Value of PBPK models in risk assessments
The need for change of the current risk assessment paradigm is due to an increasing demand from risk assessors and regulators for a higher precision of risk estimates, a greater understanding of uncertainty and variability (Allen, B. C. et al. 1996; Barton, H. A. et al. 1996; Clewell, H. J. et al. 1999; Cox, L. A., Jr. 1996; Delic, J. I. et al. 2000) , a more justifiable means of extrapolating across species, routes, doses and time (Clewell III, H. J. and M. E. Andersen 1987) , a more effective means of interpreting biological monitoring data (Georgopoulos, P. G. et al. 1994; ) and a reduction in reliance on animal testing (Barratt, M. D. et al. 1995; Blaauboer, B. J. et al. 1999; Blaauboer, B. J. et al. 1996; DeJongh, J. et al. 1999) .
Incorporating PBPK modelling into the risk assessment process can advance all of these objectives. Further, the shift away from standard setting toward a more cost-benefit analysis approach to risk assessment should also see an increase in the utility of biologically based approaches in the support risk management decisions. These topics were addressed in presentations by Dr. George Loizou of the Health and Safety Laboratory, UK in his introduction to the meeting and Dr. Bette Meek of Health Canada in a talk on "Physiologically based pharmacokinetic models (PBPK): the needs of risk assessors". They are also the subject of many paper in the scientific literature as well as
Dr. Meek elaborated on how hazard and dose-response assessment are being driven by mode of action and data informed approaches to characterise dose-response. These evolving developments in risk assessment form the basis for the IPCS harmonization frameworks that, consequently, should also facilitate the incorporation of PBPK modelling into this process. The IPCS harmonization initiative for the risk assessment of chemicals seeks to improve methods through the pursuit of common principles and approaches by drawing on global expertise. It does not seek to standardize the process but to increase understanding and acceptance by identifying potential areas of convergence and work towards the development of analytical frameworks, guidance and associated training materials and the sharing of assessments to avoid duplication (Boobis, A. R. et al. 2006; Boobis, A. R. et al. 2007; IPCS 2005; Meek, B. et al. 2003; Meek, M. E. et al. 2003; Meek, M. E. and A. Renwick 2006; Meek, M. E. et al. 2001; Meek, M. E. et al. 2002; Sonich-Mullin, C. et al. 2001) .
Current status of implementation of PBPK models in risk assessments
Dr. Ursula Gundert-Remy described use of PBPK models in the European Union (EU) acid was predicted to be 3 times lower in people than in rat, but was still not used. There was no explanation as to why the modelling results for cyclohexane and methylmethacrylate were not used. In the case of vinyl acetate, 2-butoxyethanol, and propylene methyl glycol (1-methoxypropan-2-ol) the interspecies uncertainty factor was reduced based upon analyses using the PBPK models. As result of the quantification of the interspecies differences in glutathione depletion in lung cells, the classification of styrene as a category 2 carcinogen was changed to category 3.
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Dr. Gundert-Remy was unable to discern if the application and acceptance of PBPK models in RARs was dependent upon access to PBPK expertise within any given RMS.
The lack of a standardized procedure for the evaluation of a PBPK models and their output was the main concern that prevented application in other chemical risk assessments. Dr. Gundert-Remy was not aware of the approach to evaluation of the PBPK models used in these risk assessments. However, these examples of the use of PBPK modelling by RMS and acceptance by other Member State delegates indicate a shift in risk assessment practices.
In the UK PBPK modelling has been used by the Health and Safety Executive (HSE) in a number of ways in support of its regulatory activities. A PBPK model for formaldehyde was formulated and used to support the position that formaldehyde should not be regarded as an established cause of leukemia in humans and should be considered unlikely to do so (Franks, S. J. 2005) . The validity of a biomarker of exposure for 2-butoxyethanol was studied using a PBPK model (Franks, S. J. et al. 2006 ) and the robustness of past regulatory decisions were examined using PBPK models and Monte
Carlo sampling (Delic, J. I. et al. 2000) .
In EPA 1987) . FDA raised concerns about the potential for teratogenicity of dermally applied all-trans retinoic acid that were addressed by PBPK modelling and evaluation of several potential dose metrics for the active morphogen (Clewell, H. J., 3rd et al. 1997; Rowland, M. et al. 2004) . The EPA has used PBPK models for several chemicals in addition to methylene chloride in IRIS assessment (Dewoskin, R. S. et al. 2006) . These include the cancer assessment for vinyl chloride and noncancer assessments for vinyl chloride, ethylene glycol monobutyl ether, and xylene. PBPK models have been considered for, but not applied, in the IRIS assessments for acetone, chloroform, and methyl ethyl ketone. IRIS assessments are ongoing for a number of other chemicals that propose to use PBPK models, such as that for trichloroethylene .
What can we learn from other similar experiences?
While use of quantitative modelling for toxicology, particularly for biologically based dose-response analyses, has been limited, modelling has been used extensively for environmental fate and transport in European, Canadian, and US regulatory contexts. In the US (Canada?, Europe?), risk assessments for specific contaminated sites or permitting of industrial facilities also rely heavily on often complex models for exposure pathways including food chains (US EPA 1989). Interest in reading across chemicals to make predictions has also created efforts to describe some GMPs for quantitative structure activity relationship (QSAR) models. These experiences provide perspectives potentially useful for the development of GMPs for PBPK modelling.
Environmental Modelling-Achieving Acceptance in the Regulatory World
Dr. Gerhard Goerlitz of Bayer Crop Science who had participated in the process in
Europe described the development of good practice in environmental fate modelling.
Environmental fate modelling was adopted as a regulatory tool in the European Union (EU) as a result of two major issues. The first was EU legislation in the late 1980s which, set a maximum pesticide residue concentration of 0.1 μg L -1 in both drinking and ground water and the second was the very long time, typically 3 to 4 years, required to conduct lysimeter 4 studies. The latter problem meant that decisions on the identification of critical products and their uses as required by agriculture, while avoiding contamination of groundwater resources, could not be made rapidly. Environmental fate modelling was recognized as a promising approach to address these issues, but questions were raised concerning whether model predictions were sufficiently reliable and how the integrity of model calculations could be ensured. Clear divisions in attitudes emerged following initial discussions among environmental fate modellers, regulators, and registrants.
Researchers used the models for the investigation of processes and systems, requiring flexibility and adaptability while maintaining full control of processes and algorithms in the models. Regulators and registrants wanted to predict exceedence or adherence to a regulatory limit, requiring scientific and legal certainty and preferred the use of models for which the code was not subject to alteration, provided complete documentation with clear audit trails for calculations and prevented accidental or intentional misuse. Further conflicts arose because version control and documentation of research models was frequently rudimentary, if it existed, no guidance on the selection of appropriate input parameters was available, and it was rarely properly established whether a model design was really suitable for regulatory purposes. These problems were a reflection of the fact that the typical research model was intended for use by a specialist with specific and intensive training, which at the time was almost totally lacking in regulatory agencies and in companies trying to assess the environmental behavior of plant protection products.
The natural consequence was general confusion with different modellers arriving at completely different results while supposedly using the same models for the same problem.
The first attempt to address this problem was a technical quick fix in the form of software packages comprising models and preconfigured scenarios with a user-friendly graphical interface. As a consequence, non-expert users still produced poor results increasing confusion further. There were two main reasons for this, (i) model processes, algorithms and standard parameters did not appropriately reflect substance properties and (ii) substance data from standard environmental fate studies were conceptually different from the model implementations. This led to a proposal to apply good laboratory practice (GLP) for modelling because GLP was supposed to ensure that all data could be traced and reviewed and accidental input of incorrect data, as well as forgery, could be detected.
Also, GLP had just been successfully been transferred from toxicology into the metabolism, environmental fate and residue analysis laboratories. On the other hand, measurements are never perfectly reproducible (especially not for living systems)
whereas simulations are and GLP is difficult to apply to electronic data systems and calculations. A solution was found in a short document entitled, "Rules for the correct performance and evaluation of model calculations for simulation of the environmental behavior of pesticides". Later to be known as the 'Codex' this document was produced as a result of cooperation between two German regulatory agencies, a research institute and the German Agrochemical Industry 5 . The Codex outlined general principles of GMP, not a detailed "cooking recipe" type of guidance. It focused on leaching models but was generally applicable to other simulation models. It covered the following topics:
• Selection of models
• Documentation of models
• Validation
• Support
• Official recognition and version control
• Selection and treatment of input data
• Consistency of input data and models
• Documentation of simulations
• Reporting
• Interpretation
The "Codex" created a basis for the regulatory acceptance of simulation models on the national scale in Germany, as well as forming a platform to address the requirements of 
QSAR dossiers
Recent activities within the EU with regard to the development of templates for the various stages in the application of quantitative structure activity relationships (QSARs) potentially provide a blueprint for good PBPK modelling practice 8 . Templates for QSAR development, prediction and reporting have been proposed. Each template is relevant to different stages of the risk assessment process. In the development template, information on the training domain, internal validation, cross validation and external validation is stored. In the prediction template the substance-specific prediction is stored. Finally, the reporting template should clearly state how the prediction should be used and applied.
Future Directions -Where do we need to go?
The following sections briefly summarize some of the major issues considered and recommendations from the workshop designed to facilitate the development of GMP for PBPK modelling as well as identify research priorities.
A. Risk Assessors needs and their role in the process
Two possible paradigms were proposed for the involvement of the risk assessor throughout the modelling process: 1) a continuous process -wherein one would try to include any issues that the risk assessor might have while the model is being developed and 2) an iterative process -that at appropriate times, would stop and evaluate model fitness for regulatory use. The former process would occur when there is an interdisciplinary team involved in the model development and characterization , while the latter is typical for models that have already been published.
Risk assessors have important roles to play in mode of action and dosimetry based risk assessments utilizing PBPK models. These include helping to define the goals for using the model in the risk assessment (Clewell, 
B. Model Development Practices
Model standardization can facilitate intra-and inter-disciplinary communications, but (Cobelli, C. et al. 1984) . The use of a hybrid of these approaches, where a simple standard model was used as a starting point and refinements that took place during the modelling workflow would be conducted with a standardized model building methodology was seen as a viable compromise. In discussing the problems caused by model code that is specific to a particular solver package, it was agreed that the use of a standard representation similar to SBML or cellML 9 would improve communication between modellers and risk assessors. This type of representation gives a structured description of the conceptual model free of mathematical equations and confusing syntax. The provision of an intuitive graphical interface such as MEGen 10 could make such standard formats more accessible to nonmodellers by allowing rapid generation of this 'PBPKML' representation.
C. Model Characterization
Models that have been developed sufficiently to obtain reasonable correspondence with available data can be characterized in a variety of ways to demonstrate that they are mathematically and computationally free of errors and to characterize the behavior of the model in the region of parameter space that is biologically plausible and reasonably approximates the available data Oreskes, N. 1998 
Roles and methods of sensitivity analysis
Sensitivity analysis is a tool for model characterization that can address a number of issues frequently raised concerning PBPK models. This was the topic of a white paper prepared for the meeting entitled "Global sensitivity analysis and its role in model development" by Dr. Martin Spendiff and Dr. George Loizou of the UK Health and Safety Laboratory, as well as being discussed in the breakout group presentation, "Fit for purpose: a proposed approach to PBPK model evaluation", given by Dr. Spendiff.
Sensitivity analyses can be used through the processes of model development, characterization, and evaluation to address issues including the following:
1. Characterize which parameters are well determined by available data.
2. Iterating with experiments, evaluate the sensitivity of parameters to new data that will be collected. Additional, formal, experimental design methods can also be used (Cho, K.-H. et al. 2003; Gueorguieva, I. et al. 2006; Nestorov, I. A. et al. 1998) .
3. For dose-response analysis predictions, evaluate the sensitivity of dose metrics predicted under the conditions relevant to the toxicity studies (or epidemiological studies)
to the parameters in the model.
4. For risk assessment, evaluate the predicted dose metrics in humans under relevant environmental exposure conditions to characterize their sensitivity with respect to the model parameters.
The many sensitivity analysis methods that exist can be grouped into two categories: . This is a variance-based global sensitivity method that is independent of any assumptions about the model structure and is effective for monotonic (exclusively increasing or decreasing predictions) and non-monotonic models (Campolongo, F., Saltelli, A. 1997) . FAST is preferable over other global methods due to its computational efficiency and capability to consider parameter interactions as well as main effects. Because PBPK models will become more complex over time, for a sensitivity analysis technique to become 'standard' for such models, it must be robust and 'future-proof'. The FAST technique satisfies these criteria. Dr. Spendiff illustrated the process with an example of a PBPK model with 57 parameters and a specified dose metric, which predicted greater than 90% variability across a population that was almost entirely determined by a small subset (<10) of the parameters. This does not mean that the PBPK model was over-specified as it is essential that the factors responsible for heterogeneity in output across all dose metrics, species and exposure scenarios are preserved. However, once the dose metric has been established, the techniques described can greatly reduce the effort required to perform a population simulation and provide estimates of human variability.
D. Model Documentation
Suggestions for documenting models in publications have been presented previously (Andersen, M. E. et al. 1995) . As noted there, model documentation must address a diverse readership. Recommendations from this workshop were to develop a standard, brief model description summary for the broad risk assessment audience and more detailed documentation for specialists. The summary would contain at least seven elements including: 
E. Model Evaluation
'Best practices' allow efficient evaluation of models through standardization, documentation, and transparency. The framework for model evaluation described by Clark et al., (Clark, L. H. et al. 2004 ) provides a useful outline for activities in a model evaluation process that has also been extended by Chiu et al., (Chiu, W. A. et al. 2007 ).
It would be valuable to further specify criteria that would assist reviewers in determining the strengths and limitation of a specific model. More complete specifications are needed for the processes to be used to implement model evaluation. Model evaluation needs to be a transparent, independent review process. While involvement of risk assessors and modellers throughout the steps leading from model development to application in risk assessment is valuable, it can impact the perception of the model evaluation as an independent process. An independent review is essential to identify and correct mistakes and to make judgments on the adequacy of the model and its supporting scientific database for purposes of implementing a model in risk assessment. Such reviews present a challenge for regulatory Agencies with limited PBPK modelling expertise, so it may be necessary to access additional expertise. It would also be valuable to be able to share model evaluations among countries, by agreeing upon a common framework and process even if the final decisions concerning model use might be different, for example due to risk assessment needs.
A major challenge of model evaluation is to provide perspective on the scientific uncertainties (i.e., inexact or incomplete information) identified with the model and its supporting scientific database. The models allow characterization of uncertainty in a way that default analyses cannot. For example, a default value of 10 for interspecies extrapolation is commonly applied, but the uncertainty for any specific chemical with 20 regard to the toxicity it causes in animals ranges from a value close to zero (the effect only occurs in the animals) to a much larger value (the effect only occurs in humans).
While the factor of 10 represents a judgment concerning the general tendency across many chemicals, it cannot describe the uncertainties for a specific chemical as one can start to estimate using biologically based modelling. However, this creates a challenge for considering whether the model adequately captures the science and, thus, should be implemented in the risk assessment.
Improving Science Supporting Models
Efforts to use PBPK models more broadly have also resulted in a range of scientific issues that require additional research. These include improving methods for using in vitro data in order to limit controlled animal and human studies, for model development by extrapolating across chemical to those with limited databases, and for better characterizing uncertainty and variability in PBPK models.
In vitro to in vivo extrapolations
During the presentation by Professor György Csanády of the GSF-Institute of Toxicology in Germany entitled "A physiological toxicokinetic model for inhaled propylene oxide in rat and human with special emphasis on the nose" he discussed the significant capabilities of this model given the complex nature of the toxicity and datasets it was addressing. He noted the apparent inability of the model to predict in vivo rat data using metabolic parameters estimated from in vitro studies (Csanady, G. A. and J. G. Filser 2007; Faller, T. H. et al. 2001; Lee, M. S. et al. 2005; Osterman-Golkar, S. et al. 2003) . Introduction of extrahepatic metabolism or reduction of the Michaelis-Menten K M constant was required, while a reduction in pulmonary ventilation rate was need at propylene oxide concentrations above 100 ppm likely reflecting respiratory irritant effects. The discussion stimulated by Professor Csanády's presentation led to agreement that the issue of in vitro to in vivo extrapolation, particularly, with regards to metabolism requires further detailed study Blaauboer, B. J. et al. 1996; DeJongh, J. et al. 1999) . Ideally, in vitro data should be readily usable in PBPK models 21 because it can limit the need for in vivo studies in animals or humans. The importance of protein and non-specific binding and partitioning of volatile substrates, in particular, between the liquid and headspace phases are fundamental to improving the utility of in vitro systems and the use of such data in PBPK models. The EU 6 th Framework Project "AcuteTox" is addressing many of these issues 11 . Therefore, in vitro metabolism data currently must be ranked lower than in vivo until more detailed models of in vitro systems demonstrate that they are reliable surrogates. In keeping with the theme of the workshop it was agreed that transparency and clear communication with regard to how in vitro data were generated and used in a model is vital. (Beliveau, M. et al. 2005) , though in vitro to in vivo extrapolation for metabolism and other aspects of pharmacokinetics is also receiving attention as noted in the previous section.
Cross chemical extrapolation
Uncertainty and variability in PBPK models
Much of the focus in the development of PBPK models has been to identify and capture the average behaviour of the key biological processes controlling a chemical's pharmacokinetics. These models have successfully assisted in evaluating biological hypotheses for mode of action (e.g., methylene chloride carcinogenesis described previously) as well as identifying previously unrecognized pharmacokinetic behaviours.
The increasing application of PBPK models in risk assessment has led to a range of efforts to better characterize the relationship between the model and supporting data and of uncertainty and variability concepts in risk assessments using PBPK models have been previously described . practitioners is paramount for the development of GMP, the guidelines must also be acceptable to regulators and risk assessors. Development of guidelines for GMP is best achieved through a cross-disciplinary exchange of experience and ideas among laboratory scientists, PBPK modellers, regulators and risk assessors. This workshop will provide input to the ongoing IPCS PBPK working group, which is striving to develop a description of GMP.
The adequacy of the GMP description can be evaluated using case studies. The case studies would then form the basis for training materials on GMPs. Some recommendations for case studies included:
14 http://www.who.int/ipcs/methods/harmonization/areas/pbpk/en/index.html
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Comparing a case with a dose metric for which data was directly available versus one where it was not.
Examples where PBPK models were accepted and used by regulatory Agencies and ones where they were rejected to insure appropriate documentation.
Comparisons of data rich chemicals with data limited chemicals including not just pharmacokinetic or metabolic data, but also mode of action data such as toxicogenomic or metabolomic data.
Illustrations of different risk assessment applications
Potential chemicals to use as case studies would include those previously noted by participants as PBPK models considered for or applied in risk assessments in Europe, Canada, and the United States. Other chemicals could include isopropanol (with acetone metabolite submodel) for noncancer endpoints, styrene as an example of an inaccessible dose metric, acrylamide as an example of great current regulatory interest with multiple proposed modes of action and target sites, butadiene due to the substantial animal modelling and uncertainty in human metabolism resulting in assessment based upon epidemiology.
Finally, development of training materials and hiring of personnel with needed expertise will be essential to facilitate implementation of mode of action and dosimetry-based risk assessment by regulatory Agencies. A strategy over a longer term would be to include a more quantitative, computationally based study of toxicology in university courses. The adaptation of a PBPK model generator tool such as MEGen as a teaching tool would be very useful in demonstrating to students how biological knowledge can be applied to solve real-world problems. Training materials are needed so that risk assessors and managers with diverse expertise can successfully interact with modellers to implement PBPK models in risk assessment. Training will also be important for modellers to learn about newer methodologies for characterizing uncertainty and variability in PBPK models or implementing local and global sensitivity analyses at appropriate stages of model maturation.
